Loading organizations...
§ Private Profile · 10 Knollwood Road, Medfield, MA
Biotech company developing inhaled therapeutics for respiratory diseases, focused on severe asthma and kinase-driven conditions.
Kinaset Therapeutics is a biotechnology company developing inhaled therapeutics for respiratory diseases, primarily focusing on kinase-driven conditions such as severe asthma. Its lead candidate, frevecitinib (KN-002), is a novel inhaled pan-JAK inhibitor designed as a non-invasive anti-inflammatory add-on to standard care for all severe asthma patients, currently dosing in clinical trials. The company operates as a virtual biotech, licensing assets and advancing their development and commercialization, and launched in 2020 with a $40 million Series A funding round. This funding was provided by lead investors including 5AM Ventures, Atlas Venture, and Gimv. Kinaset Therapeutics was established in 2013 by co-founders Robert Clarke, Roger Heerman, and Frazer Morgan. Its business model centers on biotech funded by venture capital, licenses assets and pays fees, milestones, and royalties in return while advancing development and commercialization.
Kinaset Therapeutics has raised $143.0M across 2 funding rounds.
Kinaset Therapeutics has raised $143.0M in total across 2 funding rounds.
Kinaset Therapeutics is a clinical-stage biopharmaceutical company developing inhaled therapeutics, primarily KN-002, a treatment for all patients with severe asthma regardless of inflammation cause, and frevecitinib for conditions like chronic obstructive pulmonary disease (COPD).[1][2][4][5] It targets unmet needs in respiratory diseases by creating small molecule drugs, such as JAK1 inhibitors delivered via inhalation, serving patients with severe asthma and pulmonary diseases.[1][2][4] The company solves limitations of existing therapies by offering pan-inflammatory treatments, with growth momentum shown by advancing toward clinical trials (Phase 1 for frevecitinib) since its 2021 founding.[2][3][4][5]
Kinaset Therapeutics Ltd was incorporated on September 6, 2021, as a private limited company in London, with its registered office at 71-75 Shelton Street, Covent Garden.[3] It was co-founded by Robert Clarke, PhD (CEO and Board Member), Roger Heerman, MBA (Chief Business/Operating Officer), and Frazer Morgan (Chief Development Officer), who bring significant respiratory drug development experience.[1] The idea emerged from this team's expertise, supported by scientific advisors like Professors Ian Adcock and Dave Singh, leading to early pivotal moments such as initiating clinical trials for inhaled candidates like frevecitinib (JAK1/JAK2/JAK3/TRPV1 inhibitor) starting July 30, 2021.[1][4]
Kinaset rides the trend of precision respiratory therapeutics amid rising demand for inhaled biologics and small molecules tackling chronic diseases like severe asthma and COPD, where inflammation heterogeneity limits current options.[1][2][4] Timing aligns with post-2021 biotech funding recovery and advances in JAK inhibitors, bolstered by market forces like aging populations and post-pandemic respiratory focus.[4][5] It influences the ecosystem by pioneering pan-inflammatory inhaled drugs, potentially expanding VC interest in UK/US biopharma startups via networks like Atlas and Gimv.[1]
Kinaset is poised to advance KN-002 into broader trials and expand frevecitinib data, with next accounts due September 2026 signaling sustained operations.[2][3] Trends like targeted inhalation therapies and AI-driven drug design will shape its path, potentially amplifying influence through partnerships or Phase 2 readouts.[4][5] As a focused respiratory player, it could redefine severe asthma care, building on its expert foundation to capture a slice of the growing inhaled therapeutics market.[1][2]
Kinaset Therapeutics has raised $143.0M across 2 funding rounds. Most recently, it raised $103.0M Series B in January 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 10, 2026 | $103M Series B | Anand Mehra, Henry Stusnick | 5AM Ventures, Atlas Venture, Bram Vanparys, Phd, MBA, Daniela Begolo, Pictet Alternative Advisors, Schroders Capital, Sixty Degree Capital, Vivo Capital, Willett Advisors | Announced |
| Nov 1, 2020 | $40M Series A | — | 5AM Ventures, Kevin Bitterman, Bram Vanparys, Phd, MBA | Announced |
Kinaset Therapeutics has raised $143.0M in total across 2 funding rounds.
Kinaset Therapeutics's investors include Anand Mehra, Henry Stusnick, 5AM Ventures, Atlas Venture, Bram Vanparys, PhD, MBA, Daniela Begolo, Pictet Alternative Advisors, Schroders Capital, Sixty Degree Capital, Vivo Capital, Willett Advisors, Kevin Bitterman.